RVL Pharmaceuticals, Inc.

Operator of a retinal therapeutics company intended to offer retinal disease treatment. The company provides tissue-specific delivery of potent drug products to address multiple pathophysiological pathways of retinal diseases such as age-related macular degeneration, diabetic macular edema, retinal vein occlusion, and cystoid macular edema, enabling patients to increase the cure's effectiveness, reduce its side effects and minimize the frequency of their retinal treatments.

Provider of drug discovery and development services intended to redefine care for women and men through purpose-driven science. The company's lead product candidate is relugolix, a once-daily, oral GnRH receptor antagonist. It has three late-stage clinical programs for relugolix in uterine fibroids, endometriosis, and prostate cancer. The company is also developing MVT-602, an oligopeptide kisspeptin-1 receptor agonist, that has completed a Phase 2a study for the treatment of female infertility as part of assisted reproduction.

Operator of a drug discovery and therapeutics company intended to treat and prevent the formation of metastatic disease. The company combines artificial intelligence, bioinformatics, and proprietary imaging techniques to identify which cancers are more likely to spread, enabling healthcare professionals to identify targets quicker, select the appropriate patients for therapy effectively, and improve patient outcomes.